Summit Therapeutics Management
Management criteria checks 3/4
Summit Therapeutics' CEO is Bob Duggan, appointed in Jul 2022, has a tenure of 3.33 years. directly owns 76.58% of the company’s shares, worth $9.78B. The average tenure of the management team and the board of directors is 2.3 years and 5 years respectively.
Key information
Bob Duggan
Chief executive officer
US$158.6k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.3yrs |
| CEO ownership | 76.6% |
| Management average tenure | 2.3yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying
Nov 19Summit Therapeutics: New Ivonescimab Data Raise Concerns
Apr 26Summit Therapeutics: Not Pharmacyclics, Not Yet
Apr 12Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade)
Mar 28Summit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab Program
Feb 24Health Check: How Prudently Does Summit Therapeutics (NASDAQ:SMMT) Use Debt?
Feb 22
Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)
Jan 18The Play On Summit Therapeutics
Jan 05Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial
Dec 02Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market
Oct 04Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Sep 19Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)
Sep 09Summit Therapeutics May Have Further Upside From Here
Aug 03Summit Therapeutics Stock: Plunging Despite A Win?
May 31Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
May 06Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress
Jan 30Summit Therapeutics slips on plans to terminate study for lead candidate
Oct 04Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio
Aug 17Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M
Aug 11Summit to explore additional trial for its bacteria-induced colon infection drug
Jul 14CEO
Bob Duggan (81 yo)
Mr. Robert W. Duggan, also known as Bob, had been an Interim Principal Financial Officer at Summit Therapeutics Inc. since July 02, 2021. He served as the Co-Chief Executive Officer at Summit Therapeutics...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-CEO & Executive Chairman | 3.3yrs | US$158.61k | 76.58% $ 9.8b | |
| Co-CEO, President & Director | 3.3yrs | US$1.16m | 4.84% $ 618.1m | |
| COO, CFO & Director | 2.1yrs | US$4.77m | 0.41% $ 52.7m | |
| Co-Founder | no data | no data | no data | |
| Chief Accounting Officer | 1.6yrs | no data | 0.021% $ 2.7m | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Chief Business & Strategy Officer | no data | no data | no data | |
| Chief Biometrics Officer | 4.8yrs | no data | no data | |
| Chief Regulatory | 3.6yrs | US$609.86k | no data | |
| Head of R&D Strategy | 2.3yrs | no data | no data | |
| Senior Vice President of Clinical Development | 2yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data |
Experienced Management: SMMT's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-CEO & Executive Chairman | 5.9yrs | US$158.61k | 76.58% $ 9.8b | |
| Co-CEO, President & Director | 5yrs | US$1.16m | 4.84% $ 618.1m | |
| COO, CFO & Director | 5.9yrs | US$4.77m | 0.41% $ 52.7m | |
| Co-Founder | no data | no data | no data | |
| Lead Independent Director | 4.1yrs | US$3.85m | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.4yrs | US$1.55m | 0.0067% $ 858.2k | |
| Member of Scientific Advisory board | no data | no data | no data | |
| Member of Scientific Advisory board | no data | no data | no data | |
| Member of Scientific Advisory board | no data | no data | no data |
Experienced Board: SMMT's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/20 23:58 |
| End of Day Share Price | 2025/11/20 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Summit Therapeutics Inc. is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Timothy Chiang | BTIG |
| Arlinda Lee | Canaccord Genuity |